Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: Divergence from in vitro results

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 651-657

  Hanley, M J ^a   Masse, G ^a   Harmatz, J S ^a   Court, M H ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FLURBIPROFEN; PLACEBO; POMEGRANATE EXTRACT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; POMEGRANATE JUICE; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BEVERAGES; FEMALE; FLUCONAZOLE; FLURBIPROFEN; FOOD-DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; PLANT EXTRACTS; PUNICACEAE; YOUNG ADULT;

EID: 84867868709     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.170     Document Type: Article

References (50)

1. Mertens-Talcott, S.U., Zadezensky, I., De Castro, W.V., Derendorf, H. & Butterweck, V. Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol. 46, 1390-1416 (2006). (Pubitemid 44704201)
2. Kirby, B.J. & Unadkat, J.D. Grapefruit juice, a glass full of drug interactions? Clin. Pharmacol. Ther. 81, 631-633 (2007). (Pubitemid 46625123)
3. Bailey, D.G., Malcolm, J., Arnold, O. & Spence, J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46, 101-110 (1998). (Pubitemid 28342779)
4. Greenblatt, D.J. Update on drug interactions with grapefruit juice: an evidence-based review. Pharmacy Times 76 (Jan), 95-104 (2010).
5. Farkas, D. & Greenblatt, D.J. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin. Drug Metab. Toxicol. 4, 381-393 (2008). (Pubitemid 351728513)
6. Hanley, M.J., Cancalon, P., Widmer, W.W. & Greenblatt, D.J. The effect of grapefruit juice on drug disposition. Expert Opin. Drug Metab. Toxicol. 7, 267-286 (2011).
7. von Moltke, L.L., Greenblatt, D.J., Schmider, J., Wright, C.E., Harmatz, J.S. & Shader, R.I. In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 55, 113-122 (1998). (Pubitemid 28006177)
8. Volak, L.P., Greenblatt, D.J. & von Moltke, L.L. In vitro approaches to anticipating clinical drug interactions. In Drug-Drug Interactions in Pharmaceutical Development. (ed. Li, A.P.) 75-93 (Wiley, Hoboken, NJ, 2008).
9. Farkas, D., Shader, R.I., von Moltke, L.L. & Greenblatt, D.J. Mechanisms and consequences of drug-drug interactions. In Preclinical Development Handbook: ADME and Biopharmaceutical Properties. (ed. S.C. Gad) 879-917 (Wiley-Interscience, Philadelphia, PA, 2008).
10. Greenblatt, D.J., He, P., von Moltke, L.L. & Court, M.H. The CYP3 family. In Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. (ed. C. Ioannides) 354-383 (Royal Society of Chemistry, Cambridge, UK, 2008).
11. Greenblatt, D.J. & von Moltke, L.L. Clinical studies of drug-drug interactions: design and interpretation. In Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. (eds. K.S. Pang, A.D. Rodrigues, & R.M. Peter) 625-649 (Springer, New York, 2010).
12. Obach, R.S., Walsky, R.L., Venkatakrishnan, K., Houston, J.B. & Tremaine, L.M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rankorder approach. Clin. Pharmacol. Ther. 78, 582-592 (2005).
13. Brown, H.S., Galetin, A., Hallifax, D. & Houston, J.B. Prediction of in vivo drugdrug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6, and CYP3A4. Clin. Pharmacokinet. 45, 1035-1050 (2006). (Pubitemid 44436005)
14. Obach, R.S., Walsky, R.L., Venkatakrishnan, K., Gaman, E.A., Houston, J.B. & Tremaine, L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316, 336-348 (2006). (Pubitemid 41832613)
15. Farkas, D. et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J. Clin. Pharmacol. 47, 286-294 (2007). (Pubitemid 46294718)
16. Heber, D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett. 269, 262-268 (2008).
17. Basu, A. & Penugonda, K. Pomegranate juice: a heart-healthy fruit juice. Nutr. Rev. 67, 49-56 (2009).
18. Jurenka, J.S. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern. Med. Rev. 13, 128-144 (2008).
19. Haber, S.L., Joy, J.K. & Largent, R. Antioxidant and antiatherogenic effects of pomegranate. Am. J. Health. Syst. Pharm. 68, 1302-1305 (2011).
20. Faria, A. & Calhau, C. The bioactivity of pomegranate: impact on health and disease. Crit. Rev. Food Sci. Nutr. 51, 626-634 (2011).
21. Chong, M.F., Macdonald, R. & Lovegrove, J.A. Fruit polyphenols and CVD risk: a review of human intervention studies. Br. J. Nutr. 104 (suppl. 3), S28-S39 (2010).
22. Adhami, V.M., Khan, N. & Mukhtar, H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr. Cancer 61, 811-815 (2009).
23. Nagata, M. et al. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab. Dispos. 35, 302-305 (2007). (Pubitemid 46148744)
24. Miners, J.O. & Birkett, D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998). (Pubitemid 28270907)
25. Rettie, A.E. & Jones, J.P. Clinical and toxicological relevance of CYP2C9: drugdrug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45, 477-494 (2005). (Pubitemid 40267790)
26. Komperda, K.E. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy 29, 1002-1006 (2009).
27. Jarvis, S., Li, C. & Bogle, R.G. Possible interaction between pomegranate juice and warfarin. Emerg. Med. J. 27, 74-75 (2010).
28. Greenblatt, D.J., von Moltke, L.L., Perloff, E.S., Luo, Y., Harmatz, J.S. & Zinny, M.A. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin. Pharmacol. Ther. 79, 125-133 (2006). (Pubitemid 43071237)
29. Greenblatt, D.J. et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J. Clin. Pharmacol. 46, 214-221 (2006). (Pubitemid 43149298)
30. Heber, D. et al. Safety and antioxidant activity of a pomegranate ellagitanninenriched polyphenol dietary supplement in overweight individuals with increased waist size. J. Agric. Food Chem. 55, 10050-10054 (2007). (Pubitemid 350305195)
31. Seeram, N.P. et al. Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J. Agric. Food Chem. 56, 1415-1422 (2008). (Pubitemid 351364077)
32. Kaminsky, L.S. & Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997). (Pubitemid 26425815)
33. Ushijima, K. et al. Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects. Br. J. Clin. Pharmacol. 68, 194-200 (2009).
34. Ngo, N. et al. The warfarin-cranberry juice interaction revisited: a systematic in vitro-in vivo evaluation. J. Exp. Pharmacol. 2010, 83-91 (2010).
35. Greenblatt, D.J. & von Moltke, L.L. Interaction of warfarin with drugs, natural substances, and foods. J. Clin. Pharmacol. 45, 127-132 (2005). (Pubitemid 40490435)
36. Mellen, C.K., Ford, M. & Rindone, J.P. Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. Br. J. Clin. Pharmacol. 70, 139-142 (2010).
37. Ansell, J., McDonough, M., Zhao, Y., Harmatz, J.S. & Greenblatt, D.J. The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J. Clin. Pharmacol. 49, 824-830 (2009).
38. Zikria, J., Goldman, R. & Ansell, J. Cranberry juice and warfarin: when bad publicity trumps science. Am. J. Med. 123, 384-392 (2010).
39. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, J.A. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 43, 84-91 (2003). (Pubitemid 36015447)
40. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, J.A. Differences in flurbiprofen pharmacokinetics between CYP2C91/1,1/2, and1/3 genotypes. Eur. J. Clin. Pharmacol. 58, 791-794 (2003). (Pubitemid 36577808)
41. Giancarlo, G.M., Venkatakrishnan, K., Granda, B.W., von Moltke, L.L. & Greenblatt, D.J. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57, 31-36 (2001). (Pubitemid 32391409)
42. Misaka, S. et al. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. Clin. Ther. 33, 246-252 (2011).
43. Scalbert, A. & Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr. 130, 2073S-2085S (2000). (Pubitemid 30619386)
44. Manach, C., Scalbert, A., Morand, C., Rémésy, C. & Jiménez, L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79, 727-747 (2004). (Pubitemid 41103873)
45. Spencer, J.P., Abd-el-Mohsen, M.M. & Rice-Evans, C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch. Biochem. Biophys. 423, 148-161 (2004). (Pubitemid 38198224)
46. Singleton, V.L., Orthofer, R., Lamuela-Ravent, R.M. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent. In Methods in Enzymology, Vol. 299: Oxidants and Antioxidants, Part A (ed. L. Packer) 152-178 (Academic Press, New York, 1999). (Pubitemid 28483890)
47. Venkatakrishnan, K., von Moltke, L.L. & Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111-180 (2000). (Pubitemid 30122116)
48. Greenblatt, D.J. et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. 74, 121-129 (2003). (Pubitemid 36951809)
49. Greenblatt, D.J. et al. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J. Pharm. Pharmacol. 63, 214-221 (2011).
50. Greenblatt, D.J. et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin. Pharmacol. Ther. 64, 661-671 (1998). (Pubitemid 29011386)